Expression of the CTLA-4 ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in chronic myeloid leukemiaAndreas Burchert, Christin Schütz, Sabrina Inselmann et al.|RWTH Publications (RWTH Aachen)|2016Cited by 0
DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, Christoph Roellig et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0